On Vacation this week
Will try to post by weekend. Thank you for reading. IBB down 3% to 256. 5/11/16
Large Cap Biopharmaceuticals Q1 2016 Metrics: Earnings Show Limited Growth Prospects
Large Cap Biopharma Winners and Losers -Looking for Product Growth We will sift through these metrics and new product news over the coming months to find value in these names. Most should be considered "Market Performers" with some added safety if they offer dividends. Watch Regeneron (REGN)...
Biotech Bear Market: Another Bad Day IBB Down 2.9%…Update-1 Regeneron (REGN)
Update-1 May 5 ...Biotechs Stable Today...IBB up 0.45%, XBI down 0.53% Regeneron Pharmaceuticals (REGN) up 4.74% on sales growth,but missed on EPS. Regeneron (REGN) raised 2016 sales estimates for Eyelea(R) to a 20-25% increase based on Q1 sales of $781M. Total Revenues were $1.2B including...
Failed Biotech Rally: Latest Biotech Earnings Don’t Help…ALXN AMGN CELG GILD…Update-1
Update-1 May 2 Biotechs Stop Slide...IBB up 1.12%...Green Screen Day Healthcare Stocks Regain Footing... XLV up 0.57% Biotech stocks moved up after a five day swoon but are still flat after one month. Most large caps were green with decent gains in Celgene (CELG) and Regeneron (REGN). A good...
Immuno-Oncology: New Products Provide Growth and Value: ABBV BMY
Immuno-Oncology: Sweet Spot in a Biotech Bear Market We will continue to track large cap biopharma Q1 earnings looking for value+growth ideas. The financial metrics will be tracked as we did in our original post, "Large Cap Winners and Losers" on February 16 near the 2016 bottom for the sector....